The Call Pacira BioSciences Bulls Got Right

Pacira BioSciences went from planning to expand EXPAREL’s reach through new payer contracts and partnerships to holding a signed cash bid from Viatris at US$36.50 per share. For Pacira BioSciences shareholders, the return from the start of the year was 48.8%, including dividends. If you were weighing a purchase back on 1 January 2026, what had to be believable about policy shifts, product concentration, and takeover potential to justify that risk?

Pacira BioSciences is not the only name tied to this theme. Zero in on 34 healthcare AI stocks and compare how each one is priced.

The Argument Pacira BioSciences Investors Were Really Having

The shares cost US$25.88 at the start of the period, so any case for Pacira BioSciences needed to clear that bar with a coherent story.

On the optimistic side, the bullish narrative pointed to a Fair Value of US$29, essentially the price implied if ambulatory policy shifts and partnerships played out, backed by 8.8% annual revenue growth and margins rising to 12.3%.

The more cautious view used a Fair Value of US$24, reflecting worries that tighter cost controls and tougher reimbursement could hold the future P/E to 8.8x even with 7.7% growth and 15.4% profitability.

What The Pacira BioSciences Evidence Actually Tested

Pacira BioSciences landed a signed all cash US$36.50 per share bid from Viatris, plus a tender offer backed by the Pacira board, which supported the earlier takeover optionality in the bullish case. At the same time, Q2 2026 results showed revenue at US$192.4m and net income at US$4.7m, with net margin at 2.4%. That shift into profit kept the cautious view on sustainable profitability very much alive, so the evidence cut both ways.

The clear swing factor here was whether policy and product positioning would convert into cash flow and outside interest. For other stocks built on similar stories, it can be useful to track two things after the decision date: reported net margin direction; and any concrete sale or partnership terms. Then test those directly against whatever revenue mix or policy claims the original thesis relied on.

What Pacira BioSciences' 49% Run Already Prices In

Pacira BioSciences now trades at US$36.4 from the start of the year, with this Narrative’s Fair Value sitting below that level rather than above it.

The Narrative leans on heavier R&D needs, reimbursement pressure and higher scrutiny. Anyone paying today’s price is assuming EXPAREL cash flows and the pain pipeline will carry that load, so how do those funding demands really shape future margins?

"Although Pacira BioSciences is benefiting from expanded separate reimbursement for EXPAREL and broader commercial coverage, rising non GAAP R&D spending guided to US$105m to US$115m in 2026 from quarterly levels of about US$25m to US$27m could absorb much of the incremental gross profit from higher volumes, limiting near term earnings growth even if revenue continues to rise."

The price and this Narrative do not agree. → Uncover what this Narrative says Pacira BioSciences is actually worth

Go Straight To The Source

What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.

• Company 1 - 21% below our estimate - pushes manufacturing expansion into AI-focused data center optics and photonics solutions.
• Company 2 - 37% below our estimate - leans on heavier unsided and heavy haul freight as AI tools reshape operations.
• Company 3 - 41% below our estimate - expands higher margin rental platforms for utility and infrastructure projects amid contract timing shifts.

That is three of the list. See the full list of 29 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com